Genetic, Epigenetic and Proteomic Analysis of the Kallikrein Family in Search for Novel Diagnostic Prognostic and Risk Susceptibility Algorithms for Prostate Cancer

激肽释放酶家族的遗传学、表观遗传学和蛋白质组学分析，寻找前列腺癌的新诊断预后和风险易感性算法

• 批准号: 183795
• 负责人: Diamandis Eleftherios P
• 金额: $ 7.29万
• 依托单位: Lunenfeld-Tanenbaum Research Institute (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-10-01 至 2009-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=183795&lang=en
• 关键词: Biomarkers; Epigenetics; Genetics; Kallikreins; Prostate Cancer; Proteomics

Prostate cancer (PCa), the most common cancer in men is a major health problem. The PSA blood test, which is a human kallikrein 3 (KLK3), has dramatically changed the presentation of PCa and increased the number of detectable early-stage and therefore tre

前列腺癌（PCa）是男性最常见的癌症，是一个主要的健康问题。PSA血液检测是一种人类激肽释放酶3（KLK 3），它极大地改变了PCa的表现，增加了可检测的早期前列腺癌的数量，因此，